Celyad Oncology SA, a biotechnology company, focuses on unlocking the potential of its intellectual property. Its portfolio comprises multiple foundational US patents focused on TCR-deficient T cell compositions, and it broadly covers allogeneic CAR T cell therapies. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
Frequently asked questions
What sector does Celyad SA (CYAD) operate in?
Celyad SA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Celyad SA (CYAD) current stock price?
As of the latest data, Celyad SA stock price is €0.27, with a previous close of €0.27. Celyad SA lost -€0.00 in the last trading session, representing a -0.37% loss.
What is Celyad SA (CYAD) current market capitalization?
Celyad SA market cap is approximately 12.04 million.
What is Celyad SA (CYAD) Earnings Per Share (EPS)?
The trailing EPS is €0.02.
What is Celyad SA (CYAD) Price-to-Earnings (P/E) ratio?
Celyad SA current P/E ratio is 13.45.
Does Celyad SA (CYAD) pay dividends?
No. Celyad SA does not pay a dividend.
What is Celyad SA (CYAD) beta (volatility) score?
Celyad SA has a beta of 1.212, suggesting it is more volatile than the market.
